These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 20816118

  • 1. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Am J Cardiol; 2010 Sep 15; 106(6):787-92. PubMed ID: 20816118
    [Abstract] [Full Text] [Related]

  • 2. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 15; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Curr Med Res Opin; 2011 Nov 15; 27(11):2165-73. PubMed ID: 21973199
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 15; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 5. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 15; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J.
    Am J Cardiol; 2005 Feb 15; 95(4):462-8. PubMed ID: 15695129
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.
    Am J Cardiol; 2010 Feb 15; 105(4):487-94. PubMed ID: 20152243
    [Abstract] [Full Text] [Related]

  • 8. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
    Farnier M, Steinmetz A, Retterstøl K, Császár A.
    Clin Ther; 2011 Jan 15; 33(1):1-12. PubMed ID: 21397769
    [Abstract] [Full Text] [Related]

  • 9. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 15; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 10. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

  • 11. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
    Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, Perevozskaya I, Davies MJ, Kush D, Mitchel YB, Ezetimibe/Simvastatin + Fenofibrate Study Group.
    Am Heart J; 2007 Feb 15; 153(2):335.e1-8. PubMed ID: 17239698
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
    Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, Gumbiner B, Ezetimibe Study Group.
    Eur Heart J; 2005 May 15; 26(9):897-905. PubMed ID: 15781429
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
    Chatley P, Badyal DK, Calton R, Khosla PP.
    Methods Find Exp Clin Pharmacol; 2007 Apr 15; 29(3):217-21. PubMed ID: 17520105
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
    Zieve F, Wenger NK, Ben-Yehuda O, Constance C, Bird S, Lee R, Hanson ME, Jones-Burton C, Tershakovec AM.
    Am J Cardiol; 2010 Mar 01; 105(5):656-63. PubMed ID: 20185012
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
    McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, Davies MJ, Mitchel YB, Gumbiner B.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1584-7. PubMed ID: 16630994
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am Heart J; 2009 Jan 18; 157(1):195-203. PubMed ID: 19081418
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
    Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Am J Cardiol; 2009 Feb 15; 103(4):515-22. PubMed ID: 19195513
    [Abstract] [Full Text] [Related]

  • 19. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 15; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 20. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K.
    Diabetes Res Clin Pract; 2004 May 15; 64(2):137-51. PubMed ID: 15063607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.